Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) has earned an average rating of “Moderate Buy” from the eleven research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and ten have given a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $44.25.
Several brokerages have recently commented on STOK. The Goldman Sachs Group reissued a “buy” rating on shares of Stoke Therapeutics in a research note on Thursday, September 10th. Wedbush lifted their target price on Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. Guggenheim reiterated a “buy” rating and set a $60.00 price target on shares of Stoke Therapeutics in a report on Tuesday, August 4th. JPMorgan Chase & Co. began coverage on Stoke Therapeutics in a research report on Friday, August 21st. They issued an “overweight” rating and a $40.00 price target for the company. Finally, Canaccord Genuity Group dropped their price objective on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a research note on Tuesday, August 4th.
Check Out Our Latest Stock Analysis on Stoke Therapeutics
Stoke Therapeutics Price Performance
Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.13). The business had revenue of $9.32 million during the quarter, compared to the consensus estimate of $4.89 million. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. On average, equities research analysts expect that Stoke Therapeutics will post -3.52 earnings per share for the current fiscal year.
Insider Transactions at Stoke Therapeutics
In related news, General Counsel Jonathan Allan sold 2,861 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total transaction of $91,637.83. Following the transaction, the general counsel directly owned 21,225 shares in the company, valued at approximately $679,836.75. The trade was a 11.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Barry Ticho sold 5,545 shares of the business’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $30.67, for a total transaction of $170,065.15. Following the transaction, the insider owned 20,110 shares in the company, valued at approximately $616,773.70. This trade represents a 21.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 32,916 shares of company stock worth $1,025,302 in the last quarter. 9.60% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Stoke Therapeutics
Several hedge funds have recently modified their holdings of STOK. Versant Capital Management Inc boosted its position in Stoke Therapeutics by 22.6% in the second quarter. Versant Capital Management Inc now owns 1,951 shares of the company’s stock worth $64,000 after purchasing an additional 359 shares during the last quarter. First Trust Advisors LP grew its stake in Stoke Therapeutics by 0.5% in the 1st quarter. First Trust Advisors LP now owns 163,459 shares of the company’s stock valued at $5,322,000 after purchasing an additional 780 shares during the period. Harbour Investments Inc. increased its position in shares of Stoke Therapeutics by 312.9% during the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after purchasing an additional 898 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Stoke Therapeutics during the 2nd quarter valued at $34,000. Finally, KBC Group NV bought a new stake in shares of Stoke Therapeutics during the 1st quarter worth $36,000.
About Stoke Therapeutics
Stoke Therapeutics, Inc is a biotechnology company focused on developing RNA-based medicines for severe genetic diseases. The company’s approach is designed to increase the production of functional proteins by selectively targeting RNA splicing, a process that helps determine how genetic information is translated into proteins.
Stoke’s technology is based on its TANGO platform, which uses antisense oligonucleotides to promote the inclusion of productive genetic sequences in messenger RNA.
Featured Stories
- Five stocks we like better than Stoke Therapeutics
- Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion
- Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
- Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out
- Oil May Be Stronger Than It Looks—And Diamondback Is on Sale
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
